Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

Segment information for the three months ended March 31, 2025 and 2024 is as follows (in thousands):

	Three Months Ended March 31, 2025
	Gyre Pharmaceuticals			Gyre			Other			Consolidated
Revenues	$	22,058		$	—		$	—		$	22,058
Cost of revenues		894			—			—			894
Gross profit		21,164			—			—			21,164
Operating expenses excluding cost of revenues:
Selling and marketing		10,841			—			—			10,841
Research and development		3,029			66			—			3,095
General and administrative		3,556			1,396			3			4,955
Total operating expenses excluding cost of revenues		17,426			1,462			3			18,891
Income (loss) from operations		3,738			(1,462	)		(3	)		2,273
Change in fair value of warrant liability		—			2,255			—			2,255
Other income, net		62			45			—			107
Income tax expense		(901	)		—			—			(901	)
Net income (loss)	$	2,899		$	838		$	(3	)	$	3,734
Supplemental disclosure of stock-based compensation expense:
General and administrative	$	78		$	429		$	—		$	507
Stock-based compensation total	$	78		$	429		$	—		$	507

	Three Months Ended March 31, 2024
	Gyre Pharmaceuticals			Gyre			Other		Consolidated
Revenues	$	27,172		$	—		$	—	$	27,172
Cost of revenues		979			—			—		979
Gross profit		26,193			—			—		26,193
Operating expenses excluding cost of revenues:
Selling and marketing		12,542			—			—		12,542
Research and development		2,009			173			—		2,182
General and administrative		2,257			1,141			—		3,398
Total operating expenses excluding cost of revenues		16,808			1,314			—		18,122
Income (loss) from operations		9,385			(1,314	)		—		8,071
Change in fair value of warrant liability		—			4,288			—		4,288
Other income, net		62			60			—		122
Income tax expense		(2,546	)		—			—		(2,546	)
Net income	$	6,901		$	3,034		$	—	$	9,935
Supplemental disclosure of stock-based compensation expense:
General and administrative	$	—		$	11		$	—	$	11
Stock-based compensation total	$	—		$	11		$	—	$	11

The table below presents total assets as of March 31, 2025 and December 31, 2024.

	March 31, 2025
	Gyre Pharmaceuticals		Gyre		Other		Consolidated
Total assets	$	122,351	$	7,074	$	365	$	129,790

	December 31, 2024
	Gyre Pharmaceuticals		Gyre		Other		Consolidated
Total assets	$	114,248	$	10,790	$	368	$	125,406

The table below only includes cash outflows for the purchase of property and equipment and excludes non-cash activities.

	Three Months Ended March 31, 2025
	Gyre Pharmaceuticals		Gyre		Other		Consolidated
Purchase of property and equipment	$	122	$	—	$	—	$	122

	Three Months Ended March 31, 2024
	Gyre Pharmaceuticals		Gyre		Other		Consolidated
Purchase of property and equipment	$	217	$	14	$	—	$	231